SCHEMBL6875869

SCHEMBL6875869

CS(=O)(=O)c1ncc(C(=O)O)c(Oc2ccccc2)n1.O=C(OO)c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 2/20 0.41
PDE4B Q07343 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TLR9 Q9NR96 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
PIN1 Q13526 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6878347 0.94 TDP1 (0.46) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6880246 0.91 CYP1A2 (0.40) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6883258 0.91 CYP1A2 (0.42) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6871114 0.91 CYP1A2 (0.40) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6875873 0.88 CYP1A2 (0.51) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6878351 0.84 CYP1A2 (0.42) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6877899 0.83 MEN1 (0.60) TDP1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL6016677 0.82 L3MBTL1 (0.41) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL6016523 0.81 DHODH (0.39) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL6016449 0.81 GPBAR1 (0.38) CYP1A2CYP2C9CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 TDP1 3804/4885CYP1A2 885/4885CYP2C9 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.